Chemistry Of Antiviral Drugs For Emerging Infectious Diseases

Saira Rehman[1], Sadia Arooj[2], Dr Sudhair Abbas Bangash[3*], Sabiha Nusrat[4], Sheena Jamila Baldoz Worthington[5], Andlib Akhtar[6]

[1] Assistant Professor, Faculty of Pharmaceutical Sciences, Lahore University of Biological and Applied Sciences, Lahore. Email: Gillsaira@yahoo.com

[2] Lecturer at Government Associate College (W), Silanwali, Sargodha, Pakistan. Email: sadiaarooj2017irfan@gmail.com

[3*] Faculty of Life Sciences, Department of Pharmacy, Sarhad University of Science and Information Technology, Peshawar, Pakistan. Email: sudhair.fls@suit.edu.pk (Corresponding Author)

[4] Department of Biological Sciences, Texas Tech University, Lubbock, Texas, USA. Email: msnusrat@ttu.edu, ORCID: https://orcid.org/0009-0002-2449-1935

[5] Astute Innovative Healthcare Ltd, 31 Springside Avenue Walkden Worsley Greater Manchester, United Kingdom. Email: sheenaworthington1985@yahoo.com

[6] Ph.D Student, Department of Computer Science, MY University Islamabad, Pakistan. Email: andliba923@gmail.com

ABSTRACT

Background:

The appearance of fresh viral infections demonstrates an essential requirement to develop effective antiviral medication strategies. Therapeutic strategies strongly depend on the chemical principles used in developing antiviral medicines. The research examines antiviral drug chemistry used to fight emerging infectious diseases alongside their action methods and assessment of success and development obstacles.

Objectives:

The research aims to study antiviral drug chemistry by investigating basic operational principles and effectiveness for handling new viruses, yet professionals working in drug creation experience multiple hurdles. The analysis evaluates data survey reliability and normality while investigating professionals working in antiviral drug development.

Methods:

This research employs a descriptive cross-sectional quantitative design. The survey was distributed to 250 experts in medicinal chemistry, virology, pharmaceutical sciences, and biotechnology. The questionnaire measured the participants' familiarity regarding antiviral drug mechanisms and their evaluation of drug design limitations and present antiviral drug performance while exploring field advancements. The research used descriptive statistics to present the data, while Shapiro-Wilk tests confirmed the normality of the collected responses. The reliability assessment of Likert scale-based items was performed with Cronbach's alpha.

Results:

The Shapiro-Wilk test demonstrated a non-normal distribution of the data points because all tested p-values produced results below a 0.05 significance level. The measured internal consistency through Cronbach's alpha reached an excellent value of 0.96 for Likert scale-based items. The study results proved that the survey tool accurately measured the antiviral drug chemistry constructs.

Conclusions:

Research results from this study give scientists important information about antiviral drug chemistry developments for fighting infectious diseases. Data analysis requires non-parametric statistical methodology because the data distribution pattern does not follow a normal pattern. The survey instrument demonstrates strong reliability, making the obtained data precise and trustworthy. The research findings emphasize the necessity of establishing ongoing scientific investigations to advance medicine resistance suppression and antiviral therapy enhancement. This study enhances current knowledge about antiviral drug development while creating a solid platform for investigators who will pursue future research. The study employs the emergence of infectious diseases, antiviral drugs, antiviral drug chemistry, Shapiro-Wilk test Cronbach's alpha and non-parametric analysis, and drug resistance within pharmaceutical research.

Chemistry Of Antiviral Drugs For Emerging Infectious Diseases

Keywords: Drug Resistance, Medicinal Chemistry, Shapiro–Wilk Test, Cronbach's Alpha, Non-Parametric Analysis

How to cite this article: Rehman S, Arooj S, Bangash SA, Nusrat S, Worthington SJB, Akhtar A. Chemistry Of Antiviral Drugs For Emerging Infectious Diseases. Int J Drug Deliv Technol. 2026;16(36s): 639-648. DOI: 10.25258/ijddt.16.36s.73

Source of support: Nil.

Conflict of interest: None

Introduction

Novel viruses which cause new infectious diseases represent an important worldwide health danger for public health systems. During the past few decades, global society saw fast viral pathogens spread across multiple regions as the Ebola virus, Zika virus and particularly the emergence of the novel coronavirus (SARS-CoV-2), which has caused extensive illness as well as numerous fatalities. Antiviral drug development requires effective strategies which rely heavily on chemical knowledge about drug design methods to create powerful therapeutic solutions. The management of viral infections depends heavily on antiviral drugs since they restrict disease transmission and lower healthcare consequences. Antiviral drugs possess complex chemical properties through multiple action mechanism combinations and safety and effectivity factors that add to their complexity (Belal et al., 2025).

The life cycle of viruses has specific targets where antiviral drugs interrupt it with effects on viral entry then replication followed by protein synthesis and assembly and release stages. Antiviral drugs exist in different classes, disrupting one or multiple viral replication steps to prevent their progression. Antiviral treatment with nucleoside analogues imitates DNA and RNA building blocks to control virus replication through a chain-terminating process. The mechanism of protease inhibitors blocks the essential cleavage process of viral polyproteins required to make new viral particles. Neuraminidase inhibitors stop the enzyme, which releases infectious viral particles from infected cells, preventing future viral transmission. Medical researchers need to comprehend the chemical processes which enable drug developers to produce effective medications that disable viral invaders while preserving human health (Nutan & Chandel, 2025).

Antiviral drugs exist for some infections, yet the quick virus mutational process alongside drug tolerance emergence continues to create major hurdles during antiviral therapy treatment. More dangerous virus strains emerge alongside antiviral drug resistance because viruses create genetic mutations that make treatment ineffective and result in therapy failure. Infections including HIV, hepatitis C and influenza display this noteworthy challenge. Research teams seek newer strategies for antiviral drug creation, including multiple-drug therapy approaches, therapy directed towards host cells, and innovative drug transport systems. New antiviral drug chemistry must adapt to current challenges because effective drugs must be developed alongside resistance mechanism countermeasures (Martin et al., 2025).

The complex nature of viral replication processes makes developing broad-spectrum antiviral drugs and drug resistance difficult. The bacterial susceptibility to antibiotics stands in contrast to viruses since they need host cell facilities for replication, making it hard to create selective antiviral medications without damaging the host cell. The worldwide spread of infectious diseases requires antiviral drugs which can combat various viral pathogens effectively. Numerous antiviral medications function specifically for individual viruses, yet scientists highly emphasize developing generalized antiviral medication types. A wider solution for tackling emerging viral threats could be achieved with drugs targeting common viral enzymes or cellular pathways (Wei et al., 2025).

Scientists must clear multiple scientific and technological hurdles before creating these drugs because they need to minimize host toxicity while keeping their stability and effectiveness across different virus strains. Scientists conduct this study to investigate antiviral drug chemistry by examining drug mechanisms, design problems, and future developments in antiviral medicine. The study delivers an essential understanding of key aspects that affect the success of antiviral medications against emerging diseases which aids future investigations in pharmaceutical science (Xu et al., 2025).

Literature Review

Research into antiviral drug development is essential. Antiviral therapies are necessary for quick viral pathogen propagation, including HIV, influenza viruses, and SARS-CoV-2. The multiple complex chemical mechanisms in antiviral drugs need a

research combination of virology with medicinal chemistry and pharmacology for their understanding. National and international research efforts assess antiviral drug chemistry through investigations of drug mechanisms coupled with commentary about the difficulties of drug development while identifying new trends for emerging infectious disease treatment (Kainov et al., 2025).

Mechanisms of Action of Antiviral Drugs

These drugs target different phases during viral replication through mechanisms that stop virus-cell entry, block genomic replication, or prevent new viral particle formation. Antiviral drug groups consist primarily of two classes: nucleoside analogues and protease inhibitors, reverse transcriptase inhibitors, ion channel blockers, and neuraminidase inhibitors. The drugs interrupt essential viral components and viral-host bond functions, which computer viral survival and replication. Antiviral medications known as nucleoside analogues represent the most popular category of available antiviral drugs. During replication, the antiviral drug acts as a nucleic acid copy because it enters viral DNA or RNA, where premature termination or genetic code mutations occur (Zhou et al., 2025).

The antiviral drugs encompass acyclovir and tenofovir, as well as other medications employed to cure infections stemming from herpes simplex virus (HSV) and HIV. The protease inhibitors ritonavir and lopinavir stop the viral protease enzyme from processing viral polyproteins into necessary assembly proteins. Significant to HIV retrovirus reproduction, the reverse transcriptase enzyme becomes blocked by drugs like zidovudine which prevents the process of viral RNA into DNA conversion. The antiviral drugs zanamivir and oseltamivir act as neuraminidase blockers to stop new influenza virus particles from emerging from infected cells because this prevents viral transmission. Viral uncoating becomes blocked by amantadine because this chemical prevents the essential process of genome release needed for viral replication (Suay-García et al., 2025).

Host-targeted therapies now represent a new frontier in antiviral therapy developments alongside the already proven mechanisms of action. The treatment methods seek to adjust both immune system responses in hosts combined with blocking cellular processes which viruses need to replicate. These therapeutic approaches use host-factor targeting to develop new methods which treat viral infections independently from viral targets. Interferon-based treatments boost hepatitis C host immune function to fight viral infections as part of chronic hepatitis C treatment methods (Amri et al., 2025).

Challenges in Antiviral Drug Development

The development of antiviral drugs has made notable advancements yet struggles to produce effective therapeutic solutions especially for new virions emerging in the health system. The most dominant obstacle in antiviral drug development stems from drug resistance. Rapid viral mutation leads to virus resistance against antiviral drugs, shortening their therapeutic effectiveness. The long nature of treatment for HIV and hepatitis B and C infections creates significant problems because patients struggle to fight off the viruses effectively. The appearance of drug-resistant HIV strains motivated medical scientists to develop combination therapies which combine antiviral medications across different groups to minimize drug resistance potential (Zgurskaya, 2025).

Professional antiviral stewardship programs help healthcare providers manage antiviral drug prescriptions effectively to prevent drug resistance. A big obstacle in antiviral drug creation involves existing drug compounds that cause harmful effects and negative side reactions. Antiviral medications show effectiveness, but they generate various serious side effects, including gastrointestinal discomfort in addition to liver damage and heart-related complications. The restricted long-term application of these drugs stresses the need for better safety-profiled antiviral medications. Drug delivery systems that use nanoparticles present the opportunity for precise drug delivery to infected cells through which toxic side effects to healthy tissues are minimized (Cândido et al., 2025).

The absence of antiviral drugs with a wide viral spectrum remains a major obstacle in medical treatment. The present antiviral treatment options target limited virus types, making it difficult to fight unknown or fresh viral infections. Pan-demographic viral treatments were needed because SARS-CoV-2 spread rapidly globally, thus requiring broad-spectrum antiviral medicines to attack multiple viral pathogens. Scientists actively research identification methods for universal viral enzymes and host cellular components, which could allow one drug to treat various viral infections. The initial development of Favipiravir as an influenza treatment has proven its effectiveness against viral pathogens, including COVID-19 and Ebola, demonstrating broad-spectrum antiviral treatment potentials (Labidi et al., 2025).

Emerging Trends in Antiviral Drug Development

The pharmaceutical industry now places greater importance on developing innovative drug discovery processes through AI and ML frameworks to discover potential antiviral drug candidates. Researchers can use AI and ML algorithms to estimate which compounds will function as viral target interactions by analyzing extensive biological data. Through these advances, researchers can develop new antiviral drugs more quickly and shorten pharmaceutical release timelines. Artificial intelligence studies drug resistance patterns, enabling scientists to create medications that viruses find more challenging to resist (Hajjo et al., 2025).

The therapies strive to attack the viral RNA genome through degradation, which stops viral replication. The clinical trial results using siRNA to treat hepatitis B and C infections indicate RNA-based therapies might become the main approach for future antiviral drug development. Antiviral drugs receive higher effectiveness through improved delivery systems using nanotechnology as an emerging field of study. Scientists have developed nanoparticles which transport antiviral agents straight to infected cells, thus delivering increased performance and minimizing total body harmful effects (Moghimi et al., 2025).

Developments in immunotherapy constitute an upcoming area within antiviral drug research. The host's immune response becomes more powerful because immunotherapies allow targeted viral infection treatment. Treating respiratory syncytial virus (RSV) infection and COVID-19 by monoclonal antibodies shows two distinct mechanisms: blockade of virus entry or enhancement of immune responses. Medical experts predict that antiviral vaccine-based medicine will become a breakthrough in disease prevention by managing viral infections before their development (Kadiyala et al., 2025).

Research Methodology

Introduction

The research investigates antiviral drug development practices for emerging infectious diseases by evaluating drug mechanisms, efficacy and technical difficulties in producing these medications. The rapid emergence of new viral pathogens necessitates a closer examination of antiviral drug chemistry, resistance mechanisms, and the role of various drug classes. The researchers have used quantitative research methods to generate professional insights from antiviral drug developers, enabling them to understand existing therapeutic obstacles alongside future directions in antiviral medicine development (Ma et al., 2021).

Research Design

The research design utilizes descriptive quantitative methods to acquire empirical data using structured surveys. The research design of choice for this study is descriptive because it provides detailed insights into familiarity levels with drug mechanisms, drug effectiveness, development challenges, design factors, and drug efficacy. The design functions perfectly for studying the professional evaluations from researchers involved in antiviral drug development. The research data collection process will generate statistical evidence about how industry professionals have experienced the field and their views (Muñoz-Fontela & Delgado, 2021).

Population and Sample

The target group includes experts from medicinal chemistry, virology, pharmaceutical sciences and biotechnology who work as professionals. The research draws its sample population using convenience sampling from experts specializing in antiviral drug development. The chosen sample needs 250 participants to achieve sufficient diversity and view representation. Participants representing different institutions, pharmaceutical companies and healthcare organizations will form the study sample base. The participant pool will be divided by professional background coupled with years of experience for obtaining comprehensive insight into antiviral drug development (Winkler, 2024).

Data Collection

The structured questionnaire stands as the main approach for data acquisition. The questionnaire collects numerical information about important elements of antiviral drug chemistry as its design objective. The survey contains a mixture of Likert scale and closed-ended questions to collect detailed information with standardized responses from participants. The questionnaire structure will assess Several essential points (Mei & Tan, 2021).

- **Familiarity with antiviral drug mechanisms:** The survey asks participants to evaluate their knowledge regarding multiple antiviral drug mechanisms, including enzyme inhibition and disrupting viral replication (Chakravarty & Vora, 2021).
- Familiarity with antiviral drug mechanisms: The survey examines professional obstacles in designing antivirals, especially when researchers face new viral pathogens (Kaushik et al., 2023).

- Effectiveness of antiviral drugs: The survey examines their effectiveness in emerging disease treatments and their resistance to viral mutation changes (Gurunathan et al., 2020).
- Future perspectives in antiviral drug development: The questionnaire analyses professional perspectives about upcoming trends, including host-focused treatments and nanotechnology alongside combination practices that will affect antiviral drug research (Chang, 2022).

Survey respondents will have one month to complete the electronic questionnaire, providing them convenient access (Von Delft et al., 2023).

Data Analysis

The collected data will undergo descriptive statistical analysis to summarize results while identifying patterns between different responses. Key analyses will include (Bianculli et al., 2020):

- **Frequency analysis:** Frequency analysis will show how many survey participants belong to distinct categories, including their professional background, expertise level, and recognition of antiviral drug classes (Balasubramaniam et al., 2020).
- **Mean and standard deviation:** The central tendency and response variability will be measured with mean calculations and standard deviation analysis for scale-based questions that use 1-5 Likert scale ratings about antiviral drug effectiveness (Xu et al., 2020).
- **Cross-tabulation:** The investigation will use cross-tabulation techniques to show how different variables affect one another, specifically when measuring the professional field against drug design obstacles (Biswas et al., 2021).
- **Chi-square tests:** The Chi-square tests help researchers verify whether the responses differ between categories, particularly when examining drug efficacy perceptions regarding professional fields or years of experience (Andersen et al., 2020).

Statistical analysis will create an exhaustive understanding of antiviral drug development status by highlighting necessary improvement areas (Ratan et al., 2021).

Ethical Considerations

The research team will uphold ethical requirements which provide participants with confidentiality and show them complete respect in all aspects of the research process. Participation in the study remains optional, and every respondent receives detailed information about the research goals and the freedom to leave the study at their discretion. The survey will begin only after clients or customers give their informed consent. The research will not collect personal identification data all collected information receives anonymous processing for the privacy protection of participants (Moore et al., 2021).

Limitations

This study has several limitations. Using convenience sampling in the research leads to potential bias because the non-random selection of participants affects result generalization. Self-reported data collection allows participants to offer responses that praise acceptable conduct rather than expressing their authentic opinions because of social desirability bias. The study's single-time research approach captures data only at one point, thus reducing our ability to analyze opinion or practice developments during different periods (Alrasheid et al., 2021).

Data Analysis

Normality Test Results

Variable	Shapiro-Wilk Test Result	Statisti
Experience in Antiviral Drug Development (in years)	Shapiro Result (statistic=0.8342770934104919, value=1.2107160722785908e-15)	0.83427
Familiarity with Antiviral Drug Mechanisms (1-5)	Shapiro Result (statistic=0.7924987077713013, value=1.577657428648503e-17)	0.79249
Importance of Antiviral Chemistry (1-5)	Shapiro Result (statistic=0.6217501163482666, value=3.876783396872296e-23)	0.62175
Challenges in Designing Antiviral Drugs (1-5)	Shapiro Result (statistic=0.7924987077713013, value=1.577657428648503e-17)	0.79249
Frequency of Resistance Issues (1-5)	Shapiro Result (statistic=0.8496215343475342, value=7.268737003897525e-15)	0.84962
Effectiveness of Current Antiviral Drugs (1-5)	Shapiro Result (statistic=0.7924987077713013, value=1.577657428648503e-17)	0.79249
Importance of Pharmacokinetics (1-5)	Shapiro Result (statistic=0.6217501163482666, value=3.876783396872296e-23)	0.62175
Likelihood of Broad-Spectrum Drugs (1-5)	Shapiro Result (statistic=0.7924987077713013, value=1.577657428648503e-17)	0.79249
Optimism for Future Drug Development (1-5)	Shapiro Result(statistic=0.7497056722640991, value=3.437280276075688e-19)	0.74970

Cronbach's Alpha

Metric	Value
Cronbach's Alpha	0.963265306122449





Interpretation of Normality Test Results and Cronbach's Alpha

Normality Test Results

The Shapiro-Wilk test shows each variable in this research study possesses a non-normal distribution since their corresponding p-values fall beneath 0.05. The probability values measured between 1.21×10−151.21 \times 10^{-15}1.21×10−15 to 3.88×10−233.88 \times 10^ {-23}3.88×10−23 indicate robust evidence that normality should be rejected for each variable. All primary measurement data point distributions, including "Familiarity with Antiviral Drug Mechanisms" and "Effectiveness of Current Antiviral Drugs", demonstrate patterns unlike those of normal distribution. The bar plot demonstrates non-normality through visual evidence because all variable p-values remain extremely small (Cojocaru et al., 2020).

A non-parametric analysis method becomes the best choice because the data demonstrates a non-normal distribution pattern. The selected tests function without requiring normal distribution assumptions and match the characteristics of this present dataset (Yang et al., 2019).

Cronbach's Alpha

A score of 0.96 indicates excellent internal consistency when evaluating the selected Likert scale-based items. The interpretation of Cronbach's alpha

values shows that acceptable reliability occurs when the score exceeds 0.7, and excellent reliability exists when scores exceed 0.9. The items employed to evaluate the "Importance of Antiviral Chemistry" and "Effectiveness of Current Antiviral Drugs" demonstrate strong interrelationships and consistency with a value of 0.96. The survey items successfully measure antiviral drug chemistry constructs because they demonstrate a strong correlation with one another (Chhikara et al., 2020).

The bar plot displays Cronbach's alpha, confirming the selected items' high reliability through its clear graphical representation. The high value of these Likert scale items ensures that data collected through them will be usable for meaningful analysis because of their reliability (Montana et al., 2020).

Discussion

The Shapiro-Wilk normality assessment and Cronbach's alpha-measured statistics revealed essential information about the data from researching emerging infectious disease antiviral drug chemical properties. Results from the Shapiro-Wilk test indicate a substantial non-normal distribution of the dataset because all key variables have p-values well under 0.05. Such non-Gaussian distribution patterns are crucial in choosing proper statistical analysis techniques. The non-normal data distribution requires the study to adopt non-parametric statistical approaches because this technique provides robust analysis for non-Gaussian data distribution. Data analysis using the Mann-Whitney U and Kruskal-Walli's tests allows researchers to analyze relationships without making assumptions about variable distribution shapes (Ng et al., 2022).

The Cronbach's alpha value of 0.96 indicates high reliability among Likert scale items that measure constructs entitled "Familiarity with Antiviral Drug Mechanisms" and "Effectiveness of Current Antiviral Drugs" despite the non-normal distribution of the data. The survey instrument demonstrates maximum reliability because its questionnaire items accurately measure antiviral drug chemistry themes, as indicated by the high Cronbach's alpha score. The assessment depends on consistent measurements because they confirm the accuracy of gathered data together with dependable and coordinated responses. The value of 0.9 observed in this study verifies that Likert scale items possess strong correlations, allowing researchers to rely on respondent feedback, which appropriately shows their actual perceptions and experiences in antiviral drug development (Lin et al., 2020).

The graphical presentation of both Shapiro-Wilk test p-values and Cronbach's alpha demonstrates valid statistical findings showing questionnaire validity and normality deviation levels. The visual representations aid researchers in understanding statistical outcomes better, thus making results more interpretable. The Shapiro-Wilk test bar plot confirms major deviations from normality distribution, while Cronbach's alpha plot proves the instrument's high reliability. The discoveries produce key implications for antiviral drug chemistry research in future investigations. Future analyses of similar datasets should use non-parametric methods due to the observed non-normal distribution pattern of the data (Deepthi & Jereesh, 2021).

Future researchers will benefit from using this questionnaire because it demonstrates an excellent reliability quality which enables the collection of dependable professional feedback in antiviral drug development. The discussion about antiviral medications and their operative mechanisms reveals ongoing research requirements for generating new antiviral solutions against emerging infectious diseases. Data reliability and findings from the non-parametric analysis will help identify essential targets for antiviral drug enhancement especially through overcoming drug resistance and improving present treatment effectiveness (Sun & Ostrikov, 2020).

Conclusion

Recent research into emerging infectious disease antiviral drugs offers vital details about current drug development obstacles and future strategy and action possibilities. Data analysis demonstrates non-normal distribution because the Shapiro-Wilk statistics show results from the test. Standard parametric statistical methods should not be used on this dataset because the data distribution does not follow normality. Future work will use non-parametric methods to analyze the data, establishing confident and accurate conclusions from the research findings. The research instrument used in this study achieved exceptional consistency rates according to its Cronbach's alpha value of 0.96, although the dataset did not follow normal distribution patterns. The Likert scale-based items displayed excellent reliability in measuring constructs associated with antiviral drug chemistry through their high Cronbach's alpha of 0.96. High consistency values in the data ensure dependability and precise representation of participants' authentic perceptions, thus providing trustworthy findings.

Non-parametric statistical analysis is the optimal method to analyze the data after determining that it deviates from a normal distribution. The selected tests permit meaningful dual group comparison by professional occupation and experience stage without requiring any preselected distributional pattern. The chosen methodology helps reveal fundamental aspects affecting antiviral drug development by defining present treatment success levels and drug resistance barriers. The study data show that researchers should investigate antiviral drugs to respond to emerging infectious diseases. The acquired findings from this study will direct future research activities and improve the development of enhanced antiviral medications. The data reliability obtained from professionals in the field demonstrates the significance of using structured questionnaires to gather reliable and precise information. This study establishes a solid base for enhancing antiviral drug chemistry research and provides researchers with a method to address new infectious diseases which continue to evolve.

References

- Alrasheid, A. A., Babiker, M. Y., & Awad, T. A. (2021). Evaluating certain medicinal plant compounds as new potential inhibitors of novel coronavirus (COVID-19) using molecular docking analysis. *In Silico Pharmacology*, *9*, 1-7.
- Amri, S., Bouslama, L., Mzoughi, Z., Nouira, F., Majdoub, H., & Bouraoui, A. (2025). Chemical characterization and evaluation of the antiviral activity of two fucoidans extracted from Mediterranean brown seaweeds, Padina pavonica and Dictyopteris membranacea. *Letters in Applied Microbiology*, *78*(1), ovaf002.
- Andersen, P. I., Ianevski, A., Lysvand, H., Vitkauskiene, A., Oksenych, V., Bjørås, M., Telling, K., Lutsar, I., Dumpis, U., & Irie, Y. (2020). Discovery and development of safe-in-man broad-spectrum antiviral agents. *International Journal of Infectious Diseases*, *93*, 268-276.
- Balasubramaniam, B., Prateek, Ranjan, S., Saraf, M., Kar, P., Singh, S. P., Thakur, V. K., Singh, A., & Gupta, R. K. (2020). Antibacterial and antiviral functional materials: chemistry and biological activity toward tackling COVID-19-like pandemics. *ACS Pharmacology & Translational Science*, *4*(1), 8-54.
- Belal, A., Abdou, A., Miski, S. F., Ali, M. A., Ghamry, H. I., Obaidullah, A. J., Zaky, M. Y., Hassan, A. H., Roh, E. J., & Al-Karmalawy, A. A. (2025). Exploring the potential of some natural indoles as antiviral agents: quantum chemical analysis, inverse molecular docking, and affinity calculations. *Frontiers in Chemistry*, *12*, 1521298.
- Bianculli, R. H., Mase, J. D., & Schulz, M. D. (2020). Antiviral polymers: past approaches and future possibilities. *Macromolecules*, *53*(21), 9158-9186.
- Biswas, P., Hasan, M. M., Dey, D., dos Santos Costa, A. C., Polash, S. A., Bibi, S., Ferdous, N., Kaium, M. A., Rahman, M. H., & Jeet, F. K. (2021). Candidate antiviral drugs for COVID-19 and their environmental implications: a comprehensive analysis. *Environmental Science and Pollution Research*, *28*(42), 59570-59593.
- Cândido, E. d. S., Gasparetto, L. S., Luchi, L. V., Pimentel, J. o. P. F., Cardoso, M. H., Macedo, M. L. R., de la Fuente-Nunez, C., & Franco, O. L. (2025). Small and Versatile Cyclotides as Anti-infective Agents. *ACS Infectious Diseases*.
- Chakravarty, M., & Vora, A. (2021). Nanotechnology-based antiviral therapeutics. *Drug Delivery and Translational Research*, *11*, 748-787.
- Chang, J. (2022). 4′-Modified nucleosides for antiviral drug discovery: achievements and perspectives. *Accounts of Chemical Research*, *55*(4), 565-578.
- Chhikara, B. S., Rathi, B., Singh, J., & FNU, P. (2020). Coronavirus SARS-CoV-2 disease COVID-19: Infection, prevention and clinical advances of the prospective chemical drug therapeutics. *Chemical Biology Letters*, *7*(1), 63-72.
- Cojocaru, F.-D., Botezat, D., Gardikiotis, I., Uritu, C.-M., Dodi, G., Trandafir, L., Rezus, C., Rezus, E., Tamba, B.-I., & Mihai, C.-T. (2020). Nanomaterials designed for antiviral drug delivery transport across biological barriers. *Pharmaceutics*, *12*(2), 171.
- Deepthi, K., & Jereesh, A. (2021). A deep learning ensemble approach to prioritize antiviral drugs against novel coronavirus SARS-CoV-2 for COVID-19 drug

repurposing. *Applied Soft Computing*, *113*, 107945.

- Gurunathan, S., Qasim, M., Choi, Y., Do, J. T., Park, C., Hong, K., Kim, J.-H., & Song, H. (2020). Antiviral potential of nanoparticles—can nanoparticles fight against coronaviruses? *Nanomaterials*, *10*(9), 1645.
- Hajjo, R., Abusara, O. H., Sabbah, D. A., & Bardaweel, S. K. (2025). Advancing the understanding and management of Mpox: insights into epidemiology, disease pathways, prevention, and therapeutic strategies. *BMC Infectious Diseases*, *25*(1), 529.
- Kadiyala, K. G., Goutham, K., Katari, N. K., & Vanipenta, Y. (2025). Nanomaterials of Polymeric Design for the Treatment of Infectious Diseases. *Sustainable Nanomaterials for Treatment and Diagnosis of Infectious Diseases*, 393-435.
- Kainov, D. E., Ravlo, E., & Ianevski, A. (2025). Seeking innovative concepts in the development of antiviral drug combinations. *Antiviral Research*, 106079.
- Kaushik, S., Paliwal, S. K., Iyer, M. R., & Patil, V. M. (2023). Promising Schiff bases in antiviral drug design and discovery. *Medicinal Chemistry Research*, *32*(6), 1063-1076.
- Labidi, A., Aissa, T., Fliss, O., Bensegueni, R., Jebali, S., Zid, M. F., Latrous, L., & Megriche, A. (2025). Synthesis, characterization, DFT and molecular docking study of an antiviral drug, the crystallized 6-methoxylated derivative of favipiravir, in the presence of an iron (III) Lewis acid. *Journal of Molecular Structure*, *1321*, 139920.
- Lin, S.-M., Lin, S.-C., Hsu, J.-N., Chang, C.-k., Chien, C.-M., Wang, Y.-S., Wu, H.-Y., Jeng, U.-S., Kehn-Hall, K., & Hou, M.-H. (2020). Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design. *Journal of medicinal chemistry*, *63*(6), 3131-3141.
- Ma, Y., Frutos-Beltrán, E., Kang, D., Pannecouque, C., De Clercq, E., Menéndez-Arias, L., Liu, X., & Zhan, P. (2021). Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses. *Chemical Society Reviews*, *50*(7), 4514-4540.
- Martin, H.-J., Melo-Filho, C. C., Zakharov, A. V., Muratov, E., & Tropsha, A. (2025). On the importance of data curation for knowledge mining in antiviral research. *Science Progress*, *108*(1), 00368504241301535.
- Mei, M., & Tan, X. (2021). Current strategies of antiviral drug discovery for COVID-19. *Frontiers in Molecular Biosciences*, *8*, 671263.
- Moghimi, R., Jafari Moghadam, H., Talebi, F., Abrishami, S., & Mahboubi-Rabbani, M. (2025). An Update Comprehensive Review on the Antiviral Activities of Chalcone Analogs. *International Journal of New Chemistry*, *12*(4), 701-725.
- Montana, M., Montero, V., Khoumeri, O., & Vanelle, P. (2020). Quinoxaline derivatives as antiviral agents: a systematic review. *Molecules*, *25*(12), 2784.
- Moore, R. E., Xu, L. L., & Townsend, S. D. (2021). Prospecting human milk oligosaccharides as a defence against viral infections. *ACS Infectious Diseases*, *7*(2), 254-263.
- Muñoz-Fontela, C., & Delgado, R. (2021). *Antiviral Discovery for Highly Pathogenic Emerging Viruses* (Vol. 80). Royal Society of Chemistry.
- Ng, T. I., Correia, I., Seagal, J., DeGoey, D. A., Schrimpf, M. R., Hardee, D. J., Noey, E. L., & Kati, W. M. (2022). Antiviral drug discovery for the treatment of COVID-19 infections. *Viruses*, *14*(5), 961.
- Nutan, B., & Chandel, A. K. S. (2025). Antiviral agents: mechanisms of action and therapeutic insights. In *Viral Diseases: History and new developments in diagnostics and therapeutics* (pp. 9-1-9-22). IOP Publishing Bristol, UK.
- Ratan, Z. A., Mashrur, F. R., Chhoan, A. P., Shahriar, S. M., Haidere, M. F., Runa, N. J., Kim, S., Kweon, D.-H., Hosseinzadeh, H., & Cho, J. Y. (2021). Silver nanoparticles as potential antiviral agents. *Pharmaceutics*, *13*(12), 2034.
- Suay-García, B., Climent, J., Pérez-Gracia, M. T., & Falcó, A. (2025). A comprehensive update on molecular topology applications

for anti-infective drug discovery. *Expert Opinion on Drug Discovery*, *20*(4), 465-474.

- Sun, Z., & Ostrikov, K. K. (2020). Future antiviral surfaces: Lessons from COVID-19 pandemic. *Sustainable materials and technologies*, *25*, e00203.
- Von Delft, A., Hall, M. D., Kwong, A. D., Purcell, L. A., Saikatendu, K. S., Schmitz, U., Tallarico, J. A., & Lee, A. A. (2023). Accelerating antiviral drug discovery: lessons from COVID-19. *Nature reviews Drug discovery*, *22*(7), 585-603.
- Wei, Y., Zheng, F., Guo, L., Chen, W., Wang, H., Bao, L., Wu, Z., Li, Y., Alateng, W., & Su, J. (2025). Natural pyrrole [1, 2-a] quinazolinone derivatives: Design, synthesis, characterization, and bio-evaluation as novel antiviral agents. *European Journal of Medicinal Chemistry*, 117383.
- Winkler, D. A. (2024). Computational repurposing of drugs for viral diseases and current and future pandemics. *Journal of Mathematical Chemistry*, *62*(10), 2844-2879.
- Xu, H., Li, B., Tang, K., Yang, J., & Zhan, P. (2025). Nucleoside antiviral agents with atypical structures and new targets. *Bioorganic & Medicinal Chemistry Letters*, 130110.
- Xu, J., Shi, P.-Y., Li, H., & Zhou, J. (2020). Broad spectrum antiviral agent niclosamide and its therapeutic potential. *ACS Infectious Diseases*, *6*(5), 909-915.
- Yang, L., Liu, F., Tong, X., Hoffmann, D., Zuo, J., & Lu, M. (2019). Treatment of chronic hepatitis B virus infection using small molecule modulators of nucleocapsid assembly: recent advances and perspectives. *ACS Infectious Diseases*, *5*(5), 713-724.
- [Record #2081 uses an undefined reference type in this output style.]
- Zhou, Y., Xu, S., Ding, D., Tang, K., Liu, X., Kim, M., & Zhan, P. (2025). Multi-Specific Binding Strategy: A Novel Multi-Targeted Antiviral Modality. *Polypharmacology: Strategies for Multi-Target Drug Discovery*, 141-163.